Chronic topical treatment with MRZ-99030 (0.5% or 2%, 3 µL, 3 times a day for 3 months) decreased the heavy retinal staining of amyloid and complement (C3) along the RPE / Bruch’s membrane in 24-month old C57BL/6 mice - a murine model of AMD (Fig. 6).

Chronic topical treatment with MRZ-99030 (0.5% or 2%, 3 µL, 3 times a day for 3 months) decreased retinal amyloid and complement (C3) on the photoreceptor and outer retinal layer in the 5-6 month old CFH-/- mouse model of AMD. In clearing Aβ, GAL-101 appears to normalize retinal complement system as well. Of note, in AMD patients, Aβ deposits and complement activation are also co-localized.

Age-related macular degeneration (AMD) Preclinical Data